As the House and Senate gear up for key trade hearings this week, manufacturers are watching with great concern a purported compromise between the U.S., EU, South Africa and India that would waive intellectual property rights for COVID-19 vaccines, according to POLITICO EU (subscription). The background: In October 2020, India and South Africa tabled a proposal to waive IP rights for a broad array…
Original source: https://www.nam.org/as-congress-preps-for-trade-hearings-ip-waiver-remains-troublesome-17198/